Key Quantitative Figures

  • Preferential Issue Size: ₹44,88,03,600 (Indian Rupees Forty Four Crore Eighty Eight Lakh Three Thousand and Six Hundred Only)
  • Number of Shares: 16,02,870 (Sixteen Lakh Two Thousand Eight Hundred and Seventy) fully paid-up equity shares
  • Face Value: ₹10 per share
  • Issue Price: ₹280 per share (including a premium of ₹270 per share)
  • Floor Price: ₹280 per share, determined as per SEBI ICDR Regulations, with a Relevant Date of August 14, 2026.
  • Utilization of Proceeds: Capital Expenditure (₹25.00 Crores), Working Capital Requirements (₹10.00 Crores), General Corporate Purposes (₹9.88 Crores).
  • Pre-Issue Share Capital: 1,71,50,000 shares
  • Post-Issue Share Capital: 1,87,52,870 shares
  • Pre-Issue Promoter Holding: 1,25,00,000 shares (72.89%)
  • Post-Issue Promoter Holding: 1,25,99,270 shares (67.18%)

Dates of Action

  • Notice Sent: August 21, 2026
  • AGM Date: September 14, 2026 (11:00 AM)
  • Cut-off Date for Voting Eligibility: September 7, 2026
  • Remote E-Voting Period: Commences September 11, 2026 (9:00 AM) to September 13, 2026 (5:00 PM)
  • Allotment Timeline: To be completed within 15 days of passing the special resolution, or within 15 days of receiving the last required regulatory approval.

Parties Involved

  • Regulator/Exchange: BSE Limited, SEBI, Ministry of Corporate Affairs (MCA)
  • E-Voting Agency: Central Depository Services (India) Limited (CDSL)
  • Registered Valuer: CS Ambrish N Gandhi, FCS, IP (IBBI RV Registration No.: IBBI/RV/03/2019/12508)
  • Practicing Company Secretary: CS Nalin Ganatra (COP No. 5132)
  • Proposed Allottees: 190 entities comprising individuals, HUFs, LLPs, and one corporate body (Halewood Laboratories Private Limited). A detailed list with names and allotted quantities is provided in the notice.
  • Director for Re-appointment: Mr. Chetan Shantilal Lalseta (DIN: 02547012)

Purpose / Rationale

The primary purpose of the AGM is to seek shareholder approval for a preferential issue of equity shares. The objects of the issue are to fund capital expenditure for land acquisition, manufacturing plant structure, and storage facilities; meet working capital requirements; and for general corporate purposes to ensure long-term growth and stability.

The re-appointment of Mr. Chetan Shantilal Lalseta is proposed as he retires by rotation under Section 152(6) of the Companies Act, 2013.

Financial / Operational Impact

The issuance will result in a cash inflow of ₹44.88 Crores. It will lead to a dilution of the promoter group's holding from 72.89% to 67.18%. The issued shares will rank pari-passu with existing equity shares and will be listed on BSE Limited. The shares allotted to non-promoters will be subject to a lock-in period as prescribed under SEBI ICDR Regulations.

Capital Structure Impact

The equity share capital will increase from 1,71,50,000 shares to 1,87,52,870 shares upon successful allotment.

Governance Update

The notice includes the proposal for the re-appointment of Mr. Chetan Shantilal Lalseta as a Non-Executive Director liable to retire by rotation. His brief resume, terms of appointment (sitting fees of ₹10,000 per meeting), and shareholding (nil) are disclosed.

Other Material Details

  • The AGM will be held entirely through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) without a physical venue.
  • The facility for appointment of proxies is not available for this virtual AGM.
  • The company has provided detailed instructions for shareholders to access remote e-voting and join the virtual meeting.
  • A certificate from a practicing company secretary confirms compliance with SEBI ICDR Regulations for the preferential issue.
  • The company undertakes that it is compliant with listing conditions and that its promoters/directors are not wilful defaulters.
  • The post-issue shareholding pattern is provided, indicating no change in control.

#Tags: #AptusPharma #PreferentialAllotment #AGM #SEBIDisclosure #RegulatoryCompliance #FinancialUpdate #Neutral